- Pressemitteilung BoxID 64977
Roche NimbleGen's Revolutionary Sequence Capture Technology Now Available for Use in Research Laboratories
Enabling researchers to perform targeted sequencing from any region in the genome, within any research institute, at any time they want
At the High-Throughput Sequencing Solutions lab of the University of Washington in Seattle, Sequence Capture 385K Custom Delivery Arrays are already in full use - with very good success. "We found NimbleGen Sequence Capture Arrays and protocol very easy to use and routinely observed successful capture experiments," says Michael Dorschner, Director of the unit. He also appreciates the quality control that comes with the system. "It not only provides robust equipment for the elution of target-specific templates but also a qPCR-based assay to evaluate the degree of enrichment." Besides Sequence Capture Delivery Arrays, Roche also provides validated equipment and kits, including a new instrument called Elution Station, to facilitate researchers to achieve consistent and reproducible capture results. Moreover, the cost savings of performing such cutting-edge research using NimbleGen Sequence Capture Arrays is a big advantage when compared with previous techniques. As Dorschner explains, the "Roche NimbleGen's Sequence Capture Technology provides a cost-effective alternative to PCR for the enrichment of genomic targets facilitating large-scale resequencing projects and the development of a multitude of next-generation sequencing-based assays."
Not only does the use of Sequence Capture Arrays tackle a major bottleneck in DNA sequencing system, the isolation of target genomic regions, but it also enhances the advantages of next-generation sequencing. The arrays are a perfect fit for the long reads of the 454 sequencing technology and thus enable haplotyping and identification of variations such as insertions, deletions, and SNPs down to single base pairs. Currently, captured DNA fragments can be directly utilized in the 454 system library preparation process as input for sequencing. "The Roche NimbleGen Sequence Capture System has revolutionized the way genomic regions of interest can be sequenced," says Lynne Nazareth, Associate Professor at the Human Genome Sequencing Center at Baylor College of Medicine, Houston. "The system provides the scientific community with an invaluable tool for the rapid interrogation of genetic sequences, especially when combined with the next-generation sequencing technologies. We have successfully used the capture technology to enrich for targeted genes and found the system to be user-friendly and cost-effective, thereby facilitating our resequencing projects."
Roche NimbleGen is currently developing protocols that will allow the direct addition of 454 adapters into the Sequence Capture workflow, thereby further streamlining the workflow and facilitate even faster turnaround time. The goal is to provide researchers with a more complete solution for targeted next-generation sequencing - in their own lab, on their own bench, on their own schedule.
Roche NimbleGen is a leading innovator, manufacturer and supplier of a proprietary suite of DNA microarrays, consumables, instruments and services. Roche NimbleGen uniquely produces high-density arrays of long oligo probes that provide greater information content and higher data quality necessary for studying the full diversity of genomic and epigenomic variation. The improved performance is made possible by Roche NimbleGen's proprietary Maskless Array Synthesis (MAS) technology, which uses digital light processing and rapid, high-yield photochemistry to synthesize long oligo, high-density DNA microarrays with extreme flexibility. For more information about Roche NimbleGen, please visit the company's website at www.nimblegen.com.
Diese Pressemitteilungen könnten Sie auch interessieren
Beim Deutschen Evangelischen Kirchentag ist auf dem Berliner Messegelände in der Medienmeile in Halle 3.2, Stand F 16, auch die Medienagentur...
Die Ordination von Frauen zum Dienst als Pfarrerinnen war Thema eines Podiums auf dem Deutschen Evangelischen Kirchentag, der vom 24. bis 28....